Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176826 · ClinicalTrials.gov registry record · Phase 2
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00176826 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 22 participants.
The verdict
NCT00176826, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The hypothesis is to determine if a preparative regimen of busulfan, cyclophosphamide, and antithymocyte globulin (ATG) plus allogeneic stem cell transplantation will be effective in the treatment of immune deficiencies and histiocytic disorders.
Interventions
- PROCEDURE Stem Cell Transplant
- DRUG Myeloablative conditioning regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2000-09 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176826
The ClinicalTrials.gov registry entry for NCT00176826 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stem Cell Transplant is the first listed.
NCT00176826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176826 about?
NCT00176826 is a clinical study titled "T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders". The hypothesis is to determine if a preparative regimen of busulfan, cyclophosphamide, and antithymocyte globulin (ATG) plus allogeneic stem cell transplantation will be effective in the treatment of immune deficiencies and histiocytic disorders.
What is the current status of trial NCT00176826?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2000-09. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00176826?
The interventions under investigation include: Stem Cell Transplant (PROCEDURE), Myeloablative conditioning regimen (DRUG).
Who is sponsoring clinical trial NCT00176826?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.